Partner with us to develop innovative cancer therapies.
While MAIA’s strategy is to develop our programs into Phase I and II, we are always open to developing strategic relationships and considering earlier collaboration opportunities. All of the programs described on our pipeline page are available for development collaboration. Currently, worldwide rights to all pipeline programs are owned by MAIA Biotechnology and its subsidiaries.
Chief Operating Officer